Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Diseases and Abnormalities at or Before Birth

Symptoms and General Pathology

Rare Diseases

Carcinoma, Renal Cell

Wilms Tumor

Kidney Neoplasms

Neoplasms by Histologic Type

Urologic Neoplasms

Urogenital Neoplasms

Syndrome

Neoplastic Syndromes, Hereditary

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Genetic Diseases, Inborn

Renal Cell Carcinoma

Wilms' Tumor

Antineoplastic Agents

All Drugs and Chemicals

Dermatologic Agents

Etoposide

Irinotecan

Temozolomide

Vincristine

Etoposide phosphate

Isotretinoin

Tretinoin

Topoisomerase I Inhibitors

Enzyme Inhibitors

Tubulin Modulators

Antimitotic Agents

Antineoplastic Agents, Alkylating

Alkylating Agents

Keratolytic Agents

Metronomic chemotherapy : Vincristine + Irinotécan + Témozolomide + Etoposide + Cis-Retinoic acid

Oral, 5 days/week during W1,W2,W7 and W8 (D1 to D5, D8 to D12, D43 to D47, D50 to D54)

Oral,3 weeks in a row, twice per cycle (D1 to D21, D43 to D63)

Oral, 3 weeks in a row, twice per cycle (D22 to D42, D64 to D84)

Oral, 2 weeks in a row, thrice per cycle (D15 to D28, D43 to D56, D71 to D84)

Cis-Retinoic acid

Emilie Heyman - Decoupigny

Marie Vanseymortier

Leslie ANDRY, MD

Anne NOTZ- CARRERE, MD

Dominique PLANTAZ, MD

Hélène SUDOUR-BONNANGE, MD

Cyril LERVAT, MD

Benoit DUMONT, MD

Arnauld VERSCHUUR, MD

Arnauld Verschuur, MD

Stéphanie HAOUY, MD

Estelle THEBAUD, MD

Joy BENADIBA, MD

Marie Dominique TABONE, MD

Jacinthe BONNEAU-LAGACHERIE, MD

Aude MARIE-CARDINE, MD

Sarah JANNIER, MD

Cécile BOULANGER, MD

Ludovic MANSUY, MD

Claudia PASQUALINI, MD

Arnauld VERSCHUUR, MD, PhD

This is a multicenter, interventional, non-randomized study among patients with a relapsed or refractory Wilms tumor. The study will aim to assess efficacy of metronomic chemotherapy, in terms of disease control after two cycles of metronomic chemotherapy.

The main aim of this study is to assess efficacy of metronomic chemotherapy, in terms of disease control after two cycles of metronomic chemotherapy .

Other objectives of the study include:

* To evaluate disease control obtained with metronomic chemotherapy, in terms of progression-free survival (PFS) and overall survival (OS).
* Evaluating early response after one cycle of treatment of metronomic treatment;
* Evaluating best tumor response over the whole metronomic treatment duration;
* Evaluating safety of the proposed metronomic chemotherapy;
* Evaluating the feasibility of the proposed metronomic chemotherapy.
* To evaluate quality of life using Kindl® Quality of Life questionnaire at baseline (before start of treatment), and approximately at weeks 7 and 13 of treatment

Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)

Phase 1-2 Trial Evaluating Metronomic Chemotherapy in Patients With a Relapsed or Refractory Wilms Tumor

Complete response, partial response or stable disease after 2 cycles of treatment, measured by the progression-free survival (PFS).

The time interval between study entry and date of progression (using RECIST 1.1)

The time interval between study entry and death from any cause

Using CT-scan or MRI imaging (using RECIST 1.1)

The adverse events (AE) are collected to evaluate the safety of the study treatment.

assessed in terms of frequency of dose reductions or temporary stops of treatment

Ravens-Sieberer and Bullinger Quality of Life Questionnaire will be used to measure the quality of life of the patients. The score can go from 0 to 100, and the higher score corresponds to a higher health-related quality of life

Centre Oscar Lambret

Spots Global Cancer Trial Database for multidrug chemotherapy